Skip to main content

Advertisement

SpringerLink
Log in

Post-Covid Asthenia Syndrome

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Objectives. To evaluate the efficacy and safety of combination therapy for patients with post-COVID asthenia syndrome (AS) using the multicomponent bioregulatory medicines Traumeel S, Ubichinon Compositum, and Coenzyme Compositum. Materials and methods. The study included 104 patients (median age 39 [30; 48] years) who had had COVID-19 and achieved clinical recovery from the acute infectious process and experienced AS for periods from two weeks to six months with an asthenia visual analog scale (VAS) score of at least 30 points. Before the start of the study, physical examination was conducted and patients’ conditions were assessed using questionnaires and scales: an asthenia VAS, a subjective asthenia rating scale (the Multidimensional Fatigue Inventory MFI-20), the L. D. Malkova Asthenia Syndrome Scale, the EQ-5D quality of life questionnaire, and the A. M. Vein Signs of Autonomic Disorders Questionnaire. Patients in the treatment group received Traumeel S, 1 tablet 3 times a day, along with Ubichinon Compositum and Coenzyme Compositum, 2.2 ml, intramuscularly, alternating every other day, for one month (15 injections of each drug per course of treatment). Patients in the reference group received 100 mg Eleutherococcus extract for 30 days, 2 tablets 2 times a day before meals, along with a combined B group vitamins formulation. Patients’ status was monitored at follow-up visits at two weeks and one month from the start of treatment and one month after treatment was completed. Results. Patients in the treatment group showed a positive effect. Patients in the reference group displayed no correlation between the quality of life and physical and mental asthenia, while the treatment group showed an inverse correlation with the severity of AS, such that improved quality of life was associated with decreased severity of AS. Significant reductions in headache and musculoskeletal pain were demonstrated in the treatment group. Conclusions. Combination therapy in patients with post-COVID AS using Traumeel S, Ubichinon Compositum, and Coenzyme Compositum produced better outcomes as compared with the reference group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shabrov, A. V. and Solov’eva, S. L., Asthenic Disorders in Clinical Practice. Guidelines for Diagnosis and Treatment, St. Petersburg (2010).

  2. Myakotnykh, V. S., Ostapchuk, E. S., and Postovalova, V. L., “The main diseases and syndromes seen in elderly and senile patients admitted to different types of hospital,” Usp. Gerontol., 31, No. 2, 250–259 (2018).

    CAS  Google Scholar 

  3. Akarachkova, E. S., “Diagnosis and treatment of psychoautonomic disorders in general somatic practice,” Lech. Vrach, 10, 60–64 (2010).

    Google Scholar 

  4. “Beyond myalgic encephalomyelitis/chronic fatigue syndrome: Redefining an illness,” Mil. Med., 180, No. 7, 721–723 (2015), https://doi.org/10.7205/MILMED-D-15-00085.

  5. Kotova, O. V. and Akarachkova, E. S., “Asthenic syndrome in neurological and general practice,” Ross. Med. Zh., 13, 824–829 (2016).

    Google Scholar 

  6. International Classification of Diseases, 10th ed., https://classinform.ru/mkb-10.html, acc. Jan. 23, 2023.

  7. Stormorken, E., Jason, L. A., and Kirkevold, M., “From good health to illness with post-infectious fatigue syndrome: a qualitative study of adults’ experiences of the illness trajectory,” BMC Fam. Pract., 18, No. 1, 49–52 (2017), https://doi.org/https://doi.org/10.1186/s12875-017-0614-4.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Wessely, S., Chalder, T., Hirsch, S., et al., “The prevalence and morbidity of chronic fatigue and chronic fatigue syndrome: a prospective primary care study,” Am. J. Public Health, 87, No. 9, 1449–1455 (1997), https://doi.org/https://doi.org/10.2105/ajph.87.9.1449.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Katz, B. Z., Shiraishi, Y., Mears, C. J., et al., “Chronic fatigue syndrome after infectious mononucleosis in adolescents,” Pediatrics, 124, No. 1, 189–193 (2009), https://doi.org/https://doi.org/10.1542/peds.2008-1879.

    Article  PubMed  Google Scholar 

  10. Naess, H., Nyland, M., Hausken, T., et al., “Chronic fatigue syndrome after Giardia enteritis: clinical characteristics, disability and long-term sickness absence,” BMC Gastroenterol., 12, 13 (2012), https://doi.org/https://doi.org/10.1186/1471-230X-12-13.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hickie, I., Davenport, T., Wakefield, D., et al., “Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study,” BMJ, 333, No. 7568, 575 (2006), https://doi.org/https://doi.org/10.1136/bmj.38933.585764.AE.

    Article  Google Scholar 

  12. Fukuda, K., Straus, S. E., Hickie, I., et al., “The chronic fatigue syndrome: a comprehensive approach to its definition and study,” Ann. Intern. Med., 121, No. 12, 953–959 (1994), https://doi.org/https://doi.org/10.7326/0003-4819-121-12-199412150-00009.

    Article  PubMed  CAS  Google Scholar 

  13. Rudroff, T., Fietsam, A. C., Deters, J. R., et al., “Post-COVID-19 Fatigue: Potential contributing factors,” Brain Sci., 10, No. 12, 1012 (2020), https://doi.org/10.3390/brainsci10121012.

  14. Frontera, J. A., Lewis, A., Melmed, K., et al., “Prevalence and predictors of prolonged cognitive and psychological symptoms following COVID-19 in the United States,” Front. Aging Neurosci., 19, No. 13, 690383 (2021), https://doi.org/10.3389/fnagi.2021.690383.

  15. COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19, National Institute for Health and Care Excellence (NICE), London (2020), https://pubmed.ncbi.nlm.nih.gov/33555768.

  16. Vink, M. and Vink-Niese, A., “Could cognitive behavioural therapy be an effective treatment for long COVID and post COVID-19 fatigue syndrome? Lessons from the Qure Study for Q-Fever Fatigue Syndrome,” Healthcare (Basel), 8, No. 4, 552 (2020), https://doi.org/https://doi.org/10.3390/healthcare8040552.

    Article  Google Scholar 

  17. Ortelli, P., Ferrazzoli, D., Sebastianelli, L., et al., “Neuropsychological and neurophysiological correlates of fatigue in post-acute patients with neurological manifestations of COVID-19: Insights into a challenging symptom,” J. Neurol. Sci., 15, No. 420, 117271 (2021), https://doi.org/10.1016/j.jns.2020.117271.

  18. Halpin, S. J., McIvor, C., Whyatt, G., et al., “Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation,” J. Med. Virol., 93, No. 2, 1013–1022 (2021), https://doi.org/https://doi.org/10.1002/jmv.26368.

    Article  PubMed  CAS  Google Scholar 

  19. Carod-Artal, F. J., “Post-COVID-19 syndrome: epidemiology, diagnostic criteria and pathogenic mechanisms involved,” Rev. Neurol., 72, No. 11, 384–396 (2021), https://doi.org/10.33588/rn.7211. 2021230.

  20. Larsen, N. W., Stiles, L. E., and Miglis, M. G., “Preparing for the longhaul: Autonomic complications of COVID-19,” Auton. Neurosci., 235, 102841 (2021), https://doi.org/https://doi.org/10.1016/j.autneu.2021.102841.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Lopez-Leon, S., Wegman-Ostrosky, T., Perelman, C., et al., “More than 50 long-term effects of COVID-19: a systematic review and meta-analysis,” Sci. Rep., 11, No. 1, 16144 (2021), https://doi.org/10.1038/s41598-021-95565-8.

  22. Sisó-Almirall, A., Brito-Zerón, P., Conangla Ferrín, L., et al., “Long COVID-19: Proposed primary care clinical guidelines for diagnosis and disease management,” Int. J. Environ. Res. Public Health, 18, No. 8, 43–50 (2021), https://doi.org/https://doi.org/10.3390/ijerph18084350.

    Article  CAS  Google Scholar 

  23. Karaarslan, F., Demircioglu Güneri, F., and Kardes, S., “Postdischarge rheumatic and musculoskeletal symptoms following hospitalization for COVID-19: prospective follow-up by phone interviews,” Rheumatol. Int., 41, No. 7, 1263–1271 (2021), https://doi.org/https://doi.org/10.1007/s00296-021-04882-8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Carfì, A., Bernabei, R., and Landi, F., “Persistent symptoms in patients after acute COVID-19,” JAMA, 324, No. 6, 603–605 (2020), https://doi.org/https://doi.org/10.1001/jama.2020.12603.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Yong, S. J., “Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments,” Infect. Dis (Lond.), 22, 1–18 (2021), https://doi.org/https://doi.org/10.1080/23744235.2021.1924397.

    Article  CAS  Google Scholar 

  26. Kanberg, N., Simrén, J., Edén, A., et al., “Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up,” EBioMedicine, 70, 103512 (2021), https://doi.org/https://doi.org/10.1016/j.ebiom.2021.103512.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Edén, A., Simrén, J., Price, R. W., et al., “Neurochemical biomarkers to study CNS effects of COVID-19: A narrative review and synthesis,” J. Neurochem., 159, No. 1, 61–77 (2021), https://doi.org/https://doi.org/10.1111/jnc.15459.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Baig, A. M., Khaleeq, A., Ali, U., and Syeda, H., “Evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanisms,” ACS Chem. Neurosci., 11, No. 7, 995–998 (2020), https://doi.org/https://doi.org/10.1021/acschemneuro.0c00122.

    Article  PubMed  CAS  Google Scholar 

  29. Chen, G., Wu, D., Guo, W., et al., “Clinical and immunological features of severe and moderate coronavirus disease 2019,” J. Clin. Invest., 130, No. 5, 2620–2629 (2020), https://doi.org/https://doi.org/10.1172/JCI137244.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Abenza-Abildúa, M. J., Novo-Aparicio, S., Moreno-Zabaleta, R., et al., “Encephalopathy in severe SARS-CoV2 infection: Inflammatory or infectious?” Int. J. Infect. Dis., 98, 398–400 (2020), https://doi.org/https://doi.org/10.1016/j.ijid.2020.07.020.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Costela-Ruiz, V. J., Illescas-Montes, R., Puerta-Puerta, et al., “SARS-CoV-2 infection: The role of cytokines in COVID-19 disease,” Cytokine Growth Factor Rev., 54, 62–75 (2020), https://doi.org/10.1016/j.cytogfr.2020.06.001.

  32. Kamchatnov, P. R., Solov’eva, E. Yu., Khasanova, D. R., and Fateeva, V. V., “Asthenic and cognitive disorders after COVID-19 infection,” Ross. Med. Zh. Med. Obozr. 5, No. 10, 636–641 (2021), https://doi.org/10.32364/2587-6821-2021-5-10-636-641.

  33. Zakharov, D. V. and Buryak, Yu. V., “Post-COVID-19 cognitive impairment. A modern view of the problem, pathogenesis, and treatment,” Obozr. Psikhiatr. Med. Psikhol., 55, No. 4, 97–105 (2021).

    Google Scholar 

  34. Bogolepova, A. N., Osinovskaya, N. A., Kovalenko, E. A., and Makhnovich, E. V., “Fatigue and cognitive impairment in post-COVID syndrome: possible treatment approaches,” Nevrol. Neiropsikh. Psikhosom., 13, No. 4, 88–93 (2021), https://doi.org/10.14412/2074-2711-2021-4-88-93.

  35. Zakharov, V. V., “Post-COVID syndrome from the neurology point of view,” Povedench. Nevrol., 2, 14–22 (2021), https://doi.org/10.46393/2712-9675_2021_2_14_22.

  36. Tereshin, A. E., Kir’yanova, V. V., and Reshetnik, D. A., “Correction of mitochondrial dysfunction in the complex rehabilitation of COVID-19,” Zh. Nevrol. Psikhiatr., 121, No. 8, 25–29 (2021), https://doi.org/10.17116/jnevro202112108125.

  37. Olenskaya, T. L., “Innovative methods of rehabilitation at the outpatient and home stages in patients after COVID-19 pneumonia,” Med. Sovet, No. 4, 220–229 (2021), https://doi.org/10.21518/2079-701X-2021-4-220-229.

  38. Olenskaya, T. L., Nikolaeva, A. G., Pet’ko, O. V., et al., “Application of hypobaric pressure chamber adaptation as a component of medical rehabilitation of patients after COVID-19,” Profilaktich. Med., 24, No. 4, 76–82 (2021), https://doi.org/10.17116/profmed20212404176.

  39. Shapovalov, K. G., Tsydenpilov, G. A., Luk’yanov, S. A., et al., “Prospects for the use of succinates in severe cases of coronavirus infection,” Eksperim. Klin. Farmakol., 85, 40–43 (2020), https://doi.org/10.30906/0869-2092-2020-83-10-40-43.

  40. Khasanova, D. R., Zhitkova, Yu. V., and Vaskaeva, G. R., “Post-COVID syndrome: a review of pathogenesis, neuropsychiatric manifestations, and perspectives for treatment,” Nevrol. Neiropsikh. Psikhosom., 13, No. 3, 93–98 (2021), https://doi.org/10.14412/2074-2711-2021-3-93-98.

  41. Putilina, M. V., “Asthenic disorders as a manifestation of chronic fatigue syndrome,” Zh. Nevrol. Psikhiatr., 121, No. 8, 125–130 (2021), https://doi.org/10.17116/jnevro2021121081125.

  42. Naumov, K. M., Andreeva, G. O., and Bazhenov, D. A., “Differentiated approach to the correction of autonomic disorders in long COVID-19,” Izv. Ross. Voenno-Med. Akad., 40, No. S4, 88–91 (2021).

    Google Scholar 

  43. Akhmedzhanova, L. T., Ostroumova, T. M., and Solokha, O. A., “Management of patients with pain syndromes associated with COVID-19,” Nevrol. Neiropsikh. Psikhosom., 13, No. 5, 96–101 (2021), https://doi.org/10.14412/2074-2711-2021-5-96-101.

  44. Karateev, A. E., Amirdzhanova, V. N., Nasonov, E. L., et al., “Post- COVID syndrome”: The focus is on musculoskeletal pain,” Nauchno-Praktich. Revmatol., 59, No. 3, 255–262 (2021), https://doi.org/10.47360/1995-4484-2021-255-262.

  45. Karateev, A. E., Lila, A. M., and Alekseeva, L. I., “Chronic musculoskeletal pain associated with prior SARS-CoV-2 infection,” Doctor Ru, 20, No. 7, 7–11 (2021), https://doi.org/10.31550/1727-2378-2021-20-7-7-11.

  46. Zhong, L. L., Wong, Y. P., Leung, C. Y., et al., “Effects of Chinese medicine for COVID-19 rehabilitation: a multicenter observational study,” Chin. Med., 17, 99–105 (2022), https://doi.org/https://doi.org/10.1186/s13020-022-00654-z.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Trager, R. J., Brewka, E. C., Kaiser, C. M., et al., “Acupuncture in multidisciplinary treatment for post-COVID-19 syndrome,” Med. Acupunct., 34, No. 3, 177–183 (2022), https://doi.org/https://doi.org/10.1089/acu.2021.0086.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Hawkins, J., Hires, C., Keenan, L., and Dunne, E., “Aromatherapy blend of thyme, orange, clove bud, and frankincense boosts energy levels in post-COVID-19 female patients: A randomized, double-blinded, placebo controlled clinical trial,” Complement. Ther. Med., 67, 102823 (2022), https://doi.org/https://doi.org/10.1016/j.ctim.2022.102823.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Schneider, C., Schneider, B., Hanisch, J., and van Haselen, R., “The role of a homoeopathic preparation compared with conventional therapy in the treatment of injuries: an observational cohort study,” Complement. Ther. Med., 16, No. 1, 22–27 (2008), https://doi.org/https://doi.org/10.1016/j.ctim.2007.04.004.

    Article  PubMed  Google Scholar 

  50. González de Vega, C., Speed, C., Wolfarth, B., et al., “Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: a multicentre, randomised, blinded, controlled and non-inferiority trial,” Int. J. Clin. Pract., 67, No. 10, 979–989 (2013), https://doi.org/10.1111/ijcp.12219.

  51. Dydykina, I. S., Kovalenko, P. S., Naumov, A. V., and Zotkin, E. G., “Possibilities of complex bioregulatory drugs in the treatment of diseases of the musculoskeletal system,” Effektiv. Farmakoter., 15, No. 8, 24–31 (2019).

    Google Scholar 

  52. Goldman, A. W., Burmeister, Y., Cesnulevicius, K., et al., “Bioregulatory systems medicine: an innovative approach to integrating the science of molecular networks, inflammation, and systems biology with the patient’s autoregulatory capacity?” Front. Physiol., 19, No. 6, 225 (2015), https://doi.org/10.3389/fphys.2015.00225.

  53. Kovalenko, P. S., Dydykina, I. S., Zhuravleva, M. V., and Zotkin, E. G., “From empirical results of clinical efficacy to evidence of the anti-inflammatory action of Traumeel® S in vitro and in vivo,” Effektiv. Farmakoter., 16, No. 6, 56–60 (2020), https://doi.org/10.33978/2307-3586-2020-16-6-16-20.

  54. van Haselen, R., “An integrative review of the evidence on the antihomotoxic medication Traumeel,” Ross. Med. Zh., 3, 185–197 (2017), https://www.rusmedreview.com/upload/iblock/cb5/185-197.pdf.

  55. Khaibullina, D. Kh., Maksimov, Y. N., Devlikamova, F. I., and Gubeev, B. E., “Treatment of cervicogenic headache using a multicomponent bioregulatory medicine,” Med. Sovet, No. 8, 95–101 (2020), https://doi.org/10.21518/2079-701X-2020-8-95-101.

  56. Pilipovich, A. A., “The efficacy of Traumeel S in terms of evidence- based medicine,” Consilium Medicum, 19, No. 2, 157–162 (2017).

    Article  Google Scholar 

  57. Quinzii, C. M., DiMauro, S., and Hirano, M., “Human coenzyme Q10 deficiency,” Neurochem. Res., 32, No. 4–5, 723–727 (2007), https://doi.org/https://doi.org/10.1007/s11064-006-9190-z.

    Article  PubMed  CAS  Google Scholar 

  58. Sazali, S., Badrin, S., Norhayati, M. N., and Idris, N. S., “Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine-a meta-analysis,” BMJ Open, 11, No. 1, e039358 (2021), https://doi.org/https://doi.org/10.1136/bmjopen-2020-039358.

    Article  Google Scholar 

  59. Qu, H., Guo, M., Chai, H., et al., “Effects of coenzyme Q10 on statin- induced myopathy: An updated meta-analysis of randomized controlled trials,” J. Am. Heart Assoc., 7, No. 19, e009835 (2018), https://doi.org/10.1161/JAHA.118.009835.

  60. Sharov, A. A., “Coenzyme world model of the origin of life,” Biosystems, 144, 8–17 (2016), https://doi.org/https://doi.org/10.1016/j.biosystems.2016.03.003.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Goroshko, O. A., Krasnykh, L. M., Kukes, V. G., and Zozina, V. I., “Evaluation of coenzyme Q10 redox status as a biomarker of oxidative stress,” Ved. Nauchn. Tsentra Eksp. Sredstv. Med. Primen., 9, No. 3, 146–152 (2019), https://doi.org/10.30895/1991-2919-2019-9-3-146-152.

  62. Xu, Z., Huo, J., Ding, X., et al., “Coenzyme Q10 improves lipid metabolism and ameliorates obesity by regulating CaMKII-mediated PDE4 inhibition,” Sci. Rep., 7, No. 1, 8253 (2017), https://doi.org/10.1038/s41598-017-08899-7.

  63. Gurtovenko, I. Yu., “The use of the medicines Coenzyme compositum and Ubichinon Compositum at the recovery stage of treatment of patients with coronary heart disease (angina pectoris FC II),” Vestn. Nov. Med. Tekhnol., XIII, No. 3, 80–83 (2006).

  64. B’yanki, I., “Coenzyme compositum and Ubiquinone compositum and their role in supporting mitochondrial functions,” Biologich. Med., 1, 16–32 (2016).

  65. Vein, A., Diseases of the Autonomic Nervous System.: Guidelines for Doctors, Meditsina, Moscow (1991).

  66. Glants, S., Medical and Biological Statistics, Praktika, Moscow (1998).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kazan Sate Medical Academy, Branch of the Russian Medical Academy for Continuing Professional Education, Russian Ministry of Health, Kazan, Russia

    D. Kh. Khaibullina & Y. N. Maksimov

Authors
  1. D. Kh. Khaibullina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y. N. Maksimov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Kh. Khaibullina.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 123, No. 3, pp. 61–69, March, 2023.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khaibullina, D.K., Maksimov, Y.N. Post-Covid Asthenia Syndrome. Neurosci Behav Physi 53, 1347–1354 (2023). https://doi.org/10.1007/s11055-023-01524-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-023-01524-3

Keywords

Search

Navigation